Adiponectin: An Indispensable Molecule in Rosiglitazone Cardioprotection Following Myocardial Infarction
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Rationale : Patients treated with peroxisome proliferator-activated receptor (PPAR)-γ agonist manifest favorable metabolic profiles associated with increased plasma adiponectin (APN). However, whether increased APN production as a result of PPAR-γ agonist treatment is an epiphenomenon or is causatively related to the cardioprotective actions of PPAR-γ remains unknown. Objective : To determine the role of APN in rosiglitazone (RSG) cardioprotection against ischemic heart injury. Methods and Results : Adult male wild-type (WT) and APN knockdown/knockout (APN +/− and APN −/− ) mice were treated with vehicle or RSG (20 mg/kg per day), and subjected to coronary artery ligation 3 days after beginning treatment. In WT mice, RSG (7 days) significantly increased adipocyte APN expression, elevated plasma APN levels (2.6-fold), reduced infarct size (17% reduction), decreased apoptosis (0.23±0.02% versus 0.47±0.04% TUNEL-positive in remote nonischemic area), attenuated oxidative stress (48.5% reduction), and improved cardiac function ( P <0.01). RSG-induced APN production and cardioprotection were significantly blunted ( P <0.05 versus WT) in APN +/− , and completely lost in APN −/− ( P >0.05 versus vehicle-treated APN −/− mice). Moreover, treatment with RSG for up to 14 days significantly improved the postischemic survival rate of WT mice ( P <0.05 versus vehicle group) but not APN knockdown/knockout mice. Conclusions : The cardioprotective effects of PPAR-γ agonists are critically dependent on its APN stimulatory action, suggesting that under pathological conditions where APN expression is impaired (such as advanced type 2 diabetes), the harmful cardiovascular effects of PPAR-γ agonists may outweigh its cardioprotective benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Shibata, R., Sato, K., Pimentel, D. R., Takemura, Y., Kihara, S., Ohashi, K., Funahashi, T., Ouchi, N., & Walsh, K. (2005) · Nature Medicine · doi:10.1038/nm1295 · Cited by 982
Chinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954
Diabetes Mellitus and Heart Failure
Jagasia, D., & McNulty, P. H. (2003) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2002.00901.x · Cited by 38
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Cited by
A Novel and Efficient Model of Coronary Artery Ligation and Myocardial Infarction in the Mouse
Gao, E., Lei, Y. H., Shang, X., Huang, Z. M., Zuo, L., Boucher, M., Fan, Q., Chuprun, J. K., Ma, X. L., & Koch, W. J. (2010) · Circulation Research · doi:10.1161/circresaha.110.223925 · Cited by 760
Self-citationAdiponectin regulation and function
Fang, H., & Judd, R. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170046 · Cited by 631
Adiponectin and cardiovascular health: an update
Hui, X., Lam, K. S., Vanhoutte, P. M., & Xu, A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01395.x · Cited by 286
Role of Adipokines in Cardiovascular Disease
Lau, W. B., Ohashi, K., Wang, Y., Ogawa, H., Murohara, T., Ma, X.-L., & Ouchi, N. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0458 · Cited by 178
Self-citationYan, W., Zhang, H., Liu, P., Wang, H., Liu, J., Gao, C., Liu, Y., Lian, K., Yang, L., Sun, L., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0329-1 · Cited by 169
Self-citation
Metadata
- Authors
- Tao, L., Wang, Y., Gao, E., Zhang, H., Yuan, Y., Lau, W. B., Chan, L., Koch, W. J., & Ma, X. L.
- Venue
- Circulation Research
- Published
- 2010-02-05
- Volume
- 106
- Issue
- 2
- Pages
- 409-417
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2085414252
- Cited by
- 89
- References
- 5
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.